A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517416-30-00

Acronym

MK-5909-005

Enrollment

Registered

2025-03-27

Start date

2025-03-31

Completion date

Unknown

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancers

Brief summary

Objective Response Rate (ORR)

Detailed description

Number of Participants who Experience One or More Adverse Events (AEs), Number of Participants who Discontinue Study Treatment due to an AE, Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS)

Interventions

DRUGRaludotatug Deruxtecan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR)	—

Secondary

Measure	Time frame
Number of Participants who Experience One or More Adverse Events (AEs), Number of Participants who Discontinue Study Treatment due to an AE, Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS)	—

Countries

France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026